In the wake of Diagnostic Ventures’ $1.7 billion collapse, investors have won the right to pursue class action fraud claims against the firm’s auditors at Deloitte & Touche but lost a bid to bring class claims against lawyers from Clifford Chance.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *